T1	Participants 715 728	vaccine group
T2	Participants 548 608	all the patients for 12 months before inclusion in the study
T3	Participants 179 264	Twenty patients with herpes simplex virus 1-related recurrent keratitis/keratouveitis
T4	Participants 849 863	control group,
T5	Participants 992 1002	two groups
T6	Participants 1121 1129	subjects
